<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719652</url>
  </required_header>
  <id_info>
    <org_study_id>ICAD-001</org_study_id>
    <nct_id>NCT02719652</nct_id>
  </id_info>
  <brief_title>Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis</brief_title>
  <official_title>Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiuhai Guo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracranial atherosclerotic disease (ICAD) is an important cause of ischemic stroke. The&#xD;
      occurrence of stroke caused by symptomatic ICAD is significantly different compared with&#xD;
      asymptomatic ICAD (19% vs 3.5%), suggesting that plaque vulnerability may be responsible for&#xD;
      the difference. Based on the previous high-resolution magnetic resonance vessel wall imaging&#xD;
      (HR-MRI) results, the investigators hypothesis that the feature of intracranial plaque&#xD;
      enhancement is an important imaging biomarker of plaque instability, which is closely related&#xD;
      to stroke. The investigators will establish the ICAD cohort and use HR-MRI to investigate the&#xD;
      composition, morphology and the enhancement pattern of symptomatic ICAD plaques. These&#xD;
      findings will correlate with biochemical markers, and stroke recurrence, in order to explore:&#xD;
&#xD;
        1. plaque characteristics and the enhancement features between symptomatic ICAD and&#xD;
           asymptomatic ICAD&#xD;
&#xD;
        2. the relationship between plaque enhancement and the composition of plaques;&#xD;
&#xD;
        3. relationship among enhancement features of symptomatic ICAD plaques, biomarkers with&#xD;
           different clinical significance,&#xD;
&#xD;
        4. evolution of enhancement features of symptomatic ICAD plaques under intensive medical&#xD;
           therapy.&#xD;
&#xD;
      The investigators aim to explore the correlation between vulnerable plaque stratification and&#xD;
      clinical outcomes, to explore the value of vascular responses in the pathogenicity of ICAD&#xD;
      vulnerable plaques, as well as to provide objective basis for the establishment of the&#xD;
      evaluation criteria of intracranial atherosclerotic vulnerable plaques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description:&#xD;
&#xD;
      Title: Vessel wall and Perfusion Imaging in Intracranial Atherosclerosis&#xD;
&#xD;
      Design: This is an prospective study that will study the characteristics of intracranial&#xD;
      atherosclerotic plaque and the enhancement features of symptomatic ICAD during a mean&#xD;
      follow-up of 1 year in symptomatic or asymtomatic patients with moderate to severe stenosis&#xD;
      of middle cerebral artery(MCA).&#xD;
&#xD;
      In the WASID trail,patients with at least 70% stenosis of a major intracranial artery had an&#xD;
      increased risk of recurrent stroke. However,The degree of stenosis is no longer the single&#xD;
      predictor of vulnerable atherosclerotic lesions. Vulnerable plaques are closely associated&#xD;
      with stroke recurrence.With the development of neurologic imaging, HR-MRI has unique ability&#xD;
      to provide information on plaque compositions, plaque burden and vulnerable features. Several&#xD;
      recent investigations suggest that enhancement of intracranial plaque is associated with&#xD;
      recurrent stroke. However, no corhort study has been performed.&#xD;
&#xD;
      This prospective, multicenter trail will be conducted in China. Based on the previous&#xD;
      work,participants will be divided into two groups :symtomatic ICAD and asymtomatic ICAD.&#xD;
      Neurological examination and clinical sera testing will be performed at baseline, 1 month, 3&#xD;
      months, 6 months, and 12 months.The stroke incidence rate of asymptomatic ICAD and stroke&#xD;
      recurrence rate of symptomatic ICAD will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>the number of symptomatic participants who suffer from stroke recurrence after enrollment in the territory of the stenotic MCA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>The number of participants who suffer from death after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any stroke, severe transient ischemic attack (TIA) outside the territory of symptomatic MCA</measure>
    <time_frame>at 7 days, 30 days,3 months，6 months, 12 months</time_frame>
    <description>The number of participants who suffer from any stroke, severe transient ischemic attack (TIA) outside the territory of symptomatic MCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke of asymptomatic participants</measure>
    <time_frame>1 year</time_frame>
    <description>The number of asymptomatic participants who suffer from stroke after enrollment in the territory of the stenotic MCA；</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Intracranial Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>symptomatic ICAD</arm_group_label>
    <description>symptomatic intracranial atherosclerosis diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>asymptomatic ICAD</arm_group_label>
    <description>asymptomatic intracranial atherosclerosis diseases</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with significant MCA stenosis（≥50%）on TCD, MRA, and/or CTA together with one&#xD;
        or more risk factors of atherosclerosis will be prospectively recruited. Symtomatic&#xD;
        patients will be included if they had suffered from a recent transient ischemic attack or&#xD;
        ischemic stroke(NHISS≤6) in the territory of the stenotic MCA. Asymptomatic patients will&#xD;
        be included if they had no history of cerebrovascular events or a history of an ischemic&#xD;
        event in a territory outside that the affected MCA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic patients who suffered TIA or non-severe ischemic stroke(NHISS ≤6) in one&#xD;
             week with 50% to 90% stenosis of MCA.&#xD;
&#xD;
          -  Asymptomatic patients with ≥50% MCA stenosis without history of cerebrovascular events&#xD;
             or an ischemic event in a territory outside that supplied by the affected MCA.&#xD;
&#xD;
          -  Degree of ≥50% stenosis must be conformed by MRA, CTA and/or TCD.&#xD;
&#xD;
          -  Age: 18-80 years.&#xD;
&#xD;
          -  mRS scale score of ≤2.&#xD;
&#xD;
          -  Patients who agree with future follow-up visits.&#xD;
&#xD;
          -  Patients who sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coexistent ipsilateral internal carotid stenosis（≥50%）on MRA, CTA and/or TCD.&#xD;
             Non-atherosclerotic vasculopathy, such as dissection, vasculitis,or moyamoya disease.&#xD;
&#xD;
          -  Evidence of cardioembolism, such as atrial fibrillation, mechanical prosthetic valve&#xD;
             disease, sick sinus syndrome, dilated cardiomyopathy, left ventricular thrombus, or&#xD;
             recent myocardial infarction, hemorrhage, watershed infarction, or other cerebral&#xD;
             diseases, such as vascular malformation, neoplasms, and encephalopyosis.&#xD;
&#xD;
          -  Patients who are unable to undergo HR-MRI owing to underlying medical conditions.&#xD;
&#xD;
          -  Patients who are allergic to any of the study medications, including aspirin,&#xD;
             clopidogrel,atorvastatin,or rosuvastatin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guo Xiuhai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Capital Medical University, Beijing, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qi Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Capital Medical University, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuhai Guo, MD</last_name>
    <email>guoxhxuan@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Yang, MD</last_name>
    <email>yangyangqiqi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Xuanwu hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuhai Guo, MD</last_name>
      <email>guoxhxuan@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qi Yang, MD</last_name>
      <phone>86-18910766178</phone>
      <email>yangyangqiqi@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Mossa-Basha M, Hwang WD, De Havenon A, Hippe D, Balu N, Becker KJ, Tirschwell DT, Hatsukami T, Anzai Y, Yuan C. Multicontrast high-resolution vessel wall magnetic resonance imaging and its value in differentiating intracranial vasculopathic processes. Stroke. 2015 Jun;46(6):1567-73. doi: 10.1161/STROKEAHA.115.009037. Epub 2015 May 7.</citation>
    <PMID>25953365</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahn SH, Lee J, Kim YJ, Kwon SU, Lee D, Jung SC, Kang DW, Kim JS. Isolated MCA disease in patients without significant atherosclerotic risk factors: a high-resolution magnetic resonance imaging study. Stroke. 2015 Mar;46(3):697-703. doi: 10.1161/STROKEAHA.114.008181. Epub 2015 Jan 27. Erratum in: Stroke. 2015 Sep;46(9):e222.</citation>
    <PMID>25628303</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryoo S, Cha J, Kim SJ, Choi JW, Ki CS, Kim KH, Jeon P, Kim JS, Hong SC, Bang OY. High-resolution magnetic resonance wall imaging findings of Moyamoya disease. Stroke. 2014 Aug;45(8):2457-60. doi: 10.1161/STROKEAHA.114.004761. Epub 2014 Jun 19.</citation>
    <PMID>24947295</PMID>
  </results_reference>
  <results_reference>
    <citation>Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013 Nov;12(11):1106-14. doi: 10.1016/S1474-4422(13)70195-9. Review.</citation>
    <PMID>24135208</PMID>
  </results_reference>
  <results_reference>
    <citation>Vakil P, Vranic J, Hurley MC, Bernstein RA, Korutz AW, Habib A, Shaibani A, Dehkordi FH, Carroll TJ, Ansari SA. T1 gadolinium enhancement of intracranial atherosclerotic plaques associated with symptomatic ischemic presentations. AJNR Am J Neuroradiol. 2013 Dec;34(12):2252-8. doi: 10.3174/ajnr.A3606. Epub 2013 Jul 4.</citation>
    <PMID>23828109</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Xiuhai Guo</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>intracranial atherosclerotic disease（ICAD）</keyword>
  <keyword>vulnerable plaque</keyword>
  <keyword>high-resolution magnetic resonance imaging （HR-MRI）</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The date of individual participant will be recorded in case report form(CRF),which will be stored technically</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

